Filing Flows › Altimmune (ALT) › R&D spending
Altimmune (ALT) R&D spending by quarter
Altimmune's R&D spending was $18.4M in Q4 2025 (fourth quarter 2025), +23% from Q3 2025. Over the last 5 quarters it ranged from $15.0M (Q3 2025) to $19.8M (Q4 2024).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q4 2025 | $18.4M | +23% | -7% |
| Q3 2025 | $15.0M | -13% | — |
| Q2 2025 | $17.2M | +9% | — |
| Q1 2025 | $15.8M | -20% | — |
| Q4 2024 | $19.8M | — | — |
Q4 2025 at a glance
Altimmune, Q4 2025: revenue $26K (+420% year over year), net loss $27.4M, operating cash flow −$19.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is Altimmune's R&D spending?
Altimmune's R&D spending was $18.4M in Q4 2025 (fourth quarter 2025), +23% from Q3 2025.
How has Altimmune's R&D spending changed?
Over the last 5 quarters it ranged from $15.0M (Q3 2025) to $19.8M (Q4 2024).